AU2015200990B2 - Optimized Fc variants - Google Patents

Optimized Fc variants

Info

Publication number
AU2015200990B2
AU2015200990B2 AU2015200990A AU2015200990A AU2015200990B2 AU 2015200990 B2 AU2015200990 B2 AU 2015200990B2 AU 2015200990 A AU2015200990 A AU 2015200990A AU 2015200990 A AU2015200990 A AU 2015200990A AU 2015200990 B2 AU2015200990 B2 AU 2015200990B2
Authority
AU
Australia
Prior art keywords
variants
optimized
region
parent polypeptide
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015200990A
Other versions
AU2015200990A1 (en
Inventor
Christian Behrens
Khalil Bouayadi
Sylvie Jorieux
Abdelhakim Kharrat
Philippe Mondon
Celine Monnet-Mars
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010224800A external-priority patent/AU2010224800B2/en
Application filed by LFB SA filed Critical LFB SA
Priority to AU2015200990A priority Critical patent/AU2015200990B2/en
Publication of AU2015200990A1 publication Critical patent/AU2015200990A1/en
Application granted granted Critical
Publication of AU2015200990B2 publication Critical patent/AU2015200990B2/en
Priority to AU2016213792A priority patent/AU2016213792B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The present invention relates to a variant of a parent polypeptide comprising an Fc region. The said variant exhibits increased binding to FcRn as compared to the parent polypeptide and comprises at least one amino acid modification in its Fc region.
AU2015200990A 2009-03-20 2015-02-26 Optimized Fc variants Active AU2015200990B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2015200990A AU2015200990B2 (en) 2009-03-20 2015-02-26 Optimized Fc variants
AU2016213792A AU2016213792B2 (en) 2009-03-20 2016-08-11 Optimized Fc variants

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305250.4 2009-03-20
AU2010224800A AU2010224800B2 (en) 2009-03-20 2010-03-19 Optimized Fc variants
AU2015200990A AU2015200990B2 (en) 2009-03-20 2015-02-26 Optimized Fc variants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2010224800A Division AU2010224800B2 (en) 2009-03-20 2010-03-19 Optimized Fc variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016213792A Division AU2016213792B2 (en) 2009-03-20 2016-08-11 Optimized Fc variants

Publications (2)

Publication Number Publication Date
AU2015200990A1 AU2015200990A1 (en) 2015-03-19
AU2015200990B2 true AU2015200990B2 (en) 2016-07-21

Family

ID=52672553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015200990A Active AU2015200990B2 (en) 2009-03-20 2015-02-26 Optimized Fc variants

Country Status (1)

Country Link
AU (1) AU2015200990B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
AU2018215673A1 (en) * 2017-02-06 2019-07-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
EP4316502A2 (en) * 2018-04-17 2024-02-07 Heidelberg Biotech GmbH Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising nc-1-fc

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041770A1 (en) * 2004-11-12 2009-02-12 Chamberlain Aaron Keith Fc VARIANTS WITH ALTERED BINDING TO FcRn

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041770A1 (en) * 2004-11-12 2009-02-12 Chamberlain Aaron Keith Fc VARIANTS WITH ALTERED BINDING TO FcRn

Also Published As

Publication number Publication date
AU2015200990A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
WO2010106180A3 (en) Optimized fc variants
WO2008092117A3 (en) Immunoglobulins with modifications in the fcr binding region
PH12016500081B1 (en) Immunoglobulin variants and uses thereof
IL250938A0 (en) Enzymatic fusion proteins, compositions comprising the same and uses thereof
WO2012175751A3 (en) Fc variants with reduced effector functions
WO2009100260A3 (en) Compositions and methods comprising basic amino acid peptides and proteases
EP2250278A4 (en) Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications
EP2504360A4 (en) Monomeric antibody fc
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
MX2014005108A (en) Polypeptide constructs and uses thereof.
MX346700B (en) Method for improving the yield of a polypeptide.
AU2012257942A8 (en) Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2009111508A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2009111450A3 (en) Metalloproteinase 9 binding proteins
WO2010011735A3 (en) Modified bovine g-csf polypeptides and their uses
MX2012004847A (en) Gluten free structured protein product.
WO2010034718A8 (en) Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
WO2011028883A3 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
MX2010007716A (en) COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART.
WO2012090150A3 (en) New cell-penetrating peptides and uses thereof
WO2011152694A3 (en) Fusion protein having factor vii activity
WO2009137778A3 (en) Methods and compositions for genetically engineering clostridia species
WO2013071295A3 (en) Transcript optimized expression enhancement for high-level production of proteins and protein domains
WO2011041499A3 (en) Isolated rice lp2 promoter and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)